난소암 | 바이오모아

AntibodystaleAbGenomics B.V Taiwan BranchPhase 2

Neihulizumab Treatment (Neihulizumab Treatment)

Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation · FRα

#FR#Antibody#Phase2#항체#면역항체+3

AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Neoadjuvant chemotherapy+Durvalumab+Tremelimumab)

Ovarian Cancer Stage IIIC; Ovarian Cancer Stage IV · Ovarian Cancer Stage IIIC

#OvarianCancerStageIIIC#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 ACTIVE

CGTBiologicstaleBeijing GoBroad HospitalPhase 2

New donor-derived CD7 CAR T-cell (New donor-derived CD7 CAR T-cell)

T-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5

CGTBiologicstaleBeijing GoBroad HospitalPhase 2

Newly matched donor-derived CD5 CAR T-cells (Newly matched donor-derived CD5 CAR T-cells)

T-Cell Acute Lymphocytic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5

CGTBiologicstaleBeijing GoBroad HospitalPhase 1

Newly matched donor-derived FL-33 CAR T therapy (Newly matched donor-derived FL-33 CAR T therapy)

Refractory/Relapsed Acute Myeloid Leukaemia · FRα

CGTBiologicstaleM.D. Anderson Cancer CenterPhase 2

ONC-PluReceptor NK cells (ONC-PluReceptor NK cells)

Recurrent B-Cell Non-Hodgkin Lymphoma; Refractory B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4

AntibodystaleRochePhase 1

durvalumab (Imfinzi, Obinutuzumab, naptumomab estafenatox and durvalumab)

ER+ Breast Cancer; Ovarian Cancer · HER2

#HER2#Antibody#Phase1#항체#면역항체+4

AntibodystaleNordic Society of Gynaecologica…Phase 2

durvalumab (Imfinzi, Olaparib + durvalumab + UV1)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#항체#면역항체+2

AntibodystaleNational Cancer Centre, Singapo…Phase 2

Oregovomab (Oregovomab)

Epithelial Ovarian Cancer · Epithelial Ovarian Cancer

#EpithelialOvarianCancer#Antibody#Phase2#항체#면역항체+2

효능 ORR 1%임상시험 1상태 ACTIVE

AntibodystaleRochePhase 2

Orelabrutinib and Rituximab (Orelabrutinib and Rituximab)

Follicular Lymphoma; Relapsed and Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4

CGTBiologicstalePrecision BioSciences, Inc.Phase 2

PBCAR20A (PBCAR20A)

Non-Hodgkin's Lymphoma, Relapsed; Chronic Lymphoid Leukemia in Relapse · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5

효능 ORR 6%임상시험 1상태 ACTIVE

CGTBiologicstalePrecision BioSciences, Inc.Phase 1

PBCAR269A (PBCAR269A)

Relapsed/Refractory Multiple Myeloma · FRα

CGTBiologicstaleStephan Grupp MD PhDPhase 1

PHOX2B PC-CAR T Cells (PHOX2B PC-CAR T Cells)

Refractory Neuroblastoma; Relapsed Neuroblastoma · FRα

CGTBiologicstalePrecigen, IncPhase 1

PRGN-3005 UltraCAR-T cells (PRGN-3005 UltraCAR-T cells)

Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma · FRα

AntibodystaleSCRI Development Innovations, L…Phase 1

PTK787/ZK222584 and Bevacizumab (PTK787/ZK222584 and Bevacizumab)

Refractory Malignancy; Advanced Malignancies · FRα

#FR#Antibody#Phase1#항체#면역항체+4

임상시험 1상태 ACTIVE

ADCBiologicstaleM.D. Anderson Cancer CenterPhase 1

STI-6129 (Part 1, Part 1 (STI-6129))

Refractory T Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia (AML) · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3

ADCBiologicstaleM.D. Anderson Cancer CenterPhase 1

STI-6129 (Part 2, Part 2 (STI-6129))

Refractory T Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia (AML) · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3